Ligand Pharma: FDA Approves Promacta For Children With CITP - Quick Facts

(RTTNews) - Ligand Pharmaceuticals Incorporated (LGND) announced that the FDA has approved a supplemental New Drug Application (sNDA) for the use of Promacta (eltrombopag), a Novartis product, for the treatment of children six years and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. The approval was based on data from two double-blind, placebo-controlled trials. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.

Promacta was discovered as a result of research collaboration between GSK and Ligand Pharmaceuticals and developed by GSK. Promacta was acquired by Novartis in March 2015 from GSK.